Current anti-Alzheimer’s disease effect of natural products and their principal targets

Current anti-Alzheimer’s disease effect of natural products and their principal targets

Various bioactive substances isolated from natural products play a pivotal role in the prevention and cure of neurodegenerative diseases, such as Alzheimer’s disease. Currently, there are many theories about the pathogenesis of this disease. In this review we discuss among them, the cholinergic hypo...

Full description

Bibliographic Details
Main Author:	Ye Zhu, Le Peng, Jian Hu, Yan Chen, Faxiu Chen
Format:	Article
Language:	English
Published:	IMR Press 2019-09-01
Series:	Journal of Integrative Neuroscience
Subjects:	\|alzheimer’s disease\|natural products\|cholinergic hypotheses\|aβ toxicity\|tau hyperphosphorylation\|neurochemistry\|acetylcholinesterase activity
Online Access:	https://jin.imrpress.com/fileup/1757-448X/PDF/1569401903737-1165004353.pdf

Similar Items

Curcuminoids and resveratrol as anti-Alzheimer agents
by: Oliver B. Villaflores, et al.
Published: (2012-12-01)

Relevance of Phosphorylation and Truncation of Tau to the Etiopathogenesis of Alzheimer’s Disease
by: Yan Zhou, et al.
Published: (2018-02-01)

Development of p-Tau Differentiated Cell Model of Alzheimer’s Disease to Screen Novel Acetylcholinesterase Inhibitors
by: Giuseppe Uras, et al.
Published: (2022-11-01)

Natural Products in Alzheimer’s Disease Therapy: Would Old Therapeutic Approaches Fix the Broken Promise of Modern Medicines?
by: Solomon Habtemariam
Published: (2019-04-01)

Iron and Targeted Iron Therapy in Alzheimer’s Disease
by: Jian Wang, et al.
Published: (2023-11-01)

Pathological Tau From Alzheimer’s Brain Induces Site-Specific Hyperphosphorylation and SDS- and Reducing Agent-Resistant Aggregation of Tau in vivo
by: Jin Miao, et al.
Published: (2019-03-01)

Morin attenuates tau hyperphosphorylation by inhibiting GSK3β
by: Eun Ji Gong, et al.
Published: (2011-11-01)

Agomelatine Prevents Amyloid Plaque Deposition, Tau Phosphorylation, and Neuroinflammation in APP/PS1 Mice
by: Xiao-bo Yang, et al.
Published: (2022-01-01)

Anesthesia promotes acute expression of genes related to Alzheimer’s disease and latent tau aggregation in transgenic mouse models of tauopathy
by: John David Eun, et al.
Published: (2022-07-01)

Alzheimer’s Disease and Toxins Produced by Marine Dinoflagellates: An Issue to Explore
by: Maria João Botelho, et al.
Published: (2022-04-01)

Tau and mTOR: The Hotspots for Multifarious Diseases in Alzheimer's Development
by: Zeba Mueed, et al.
Published: (2019-01-01)

A nonhuman primate model with Alzheimer’s disease-like pathology induced by hippocampal overexpression of human tau
by: Zhouquan Jiang, et al.
Published: (2024-01-01)

Structure Based Design and Molecular Docking Studies for Phosphorylated Tau Inhibitors in Alzheimer’s Disease
by: Jangampalli Adi Pradeepkiran, et al.
Published: (2019-03-01)

Synthesis and biological evaluation of thieno[3,2-c]pyrazol-3-amine derivatives as potent glycogen synthase kinase 3β inhibitors for Alzheimer’s disease
by: Ning Yan, et al.
Published: (2022-12-01)

Microglia phenotypes are associated with subregional patterns of concomitant tau, amyloid-β and α-synuclein pathologies in the hippocampus of patients with Alzheimer’s disease and dementia with Lewy bodies
by: Sonja Fixemer, et al.
Published: (2022-03-01)

Astaxanthin Ameliorated Parvalbumin-Positive Neuron Deficits and Alzheimer’s Disease-Related Pathological Progression in the Hippocampus of AppNL-G-F/NL-G-F Mice
by: Nobuko Hongo, et al.
Published: (2020-03-01)

The role and therapeutic implication of protein tyrosine phosphatases in Alzheimer’s disease
by: Xia Zhao, et al.
Published: (2022-07-01)

Genome-Wide Epistasis Study of Cerebrospinal Fluid Hyperphosphorylated Tau in ADNI Cohort
by: Dandan Chen, et al.
Published: (2023-06-01)

Surfen and oxalyl surfen decrease tau hyperphosphorylation and mitigate neuron deficits in vivo in a zebrafish model of tauopathy
by: Seyedeh Maryam Alavi Naini, et al.
Published: (2018-03-01)

The Role of Traditional Chinese Medicine Natural Products in β-Amyloid Deposition and Tau Protein Hyperphosphorylation in Alzheimer’s Disease
by: Yan H, et al.
Published: (2023-11-01)

Melatonin receptor stimulation by agomelatine prevents Aβ-induced tau phosphorylation and oxidative damage in PC12 cells
by: Yao K, et al.
Published: (2019-01-01)

Similarities and Differences in the Pattern of Tau Hyperphosphorylation in Physiological and Pathological Conditions: Impacts on the Elaboration of Therapies to Prevent Tau Pathology
by: Antoine Duquette, et al.
Published: (2021-01-01)

Dendrimers and Derivatives as Multifunctional Nanotherapeutics for Alzheimer’s Disease
by: Débora A. Moreira, et al.
Published: (2023-03-01)

Associations of AT(N) biomarkers with neuropsychiatric symptoms in preclinical Alzheimer’s disease and cognitively unimpaired individuals
by: Kok Pin Ng, et al.
Published: (2021-03-01)

A novel transgenic mouse line with hippocampus-dominant and inducible expression of truncated human tau
by: Yang Gao, et al.
Published: (2023-11-01)

Topical Cellular/Tissue and Molecular Aspects Regarding Nonpharmacological Interventions in Alzheimer’s Disease—A Systematic Review
by: Sorina Aurelian, et al.
Published: (2023-11-01)

1,8-Cineole Ameliorates Advanced Glycation End Products-Induced Alzheimer’s Disease-like Pathology In Vitro and In Vivo
by: Fengmao An, et al.
Published: (2022-06-01)

Revisiting the role of acetylcholinesterase in Alzheimer’s disease: cross-talk with P-tau and β-amyloid
by: Maria-Salud eGarcía-Ayllón, et al.
Published: (2011-09-01)

Nec‐1 alleviates cognitive impairment with reduction of Aβ and tau abnormalities in APP/PS1 mice
by: Seung‐Hoon Yang, et al.
Published: (2017-01-01)

Berberine Reduces Aβ42 Deposition and Tau Hyperphosphorylation via Ameliorating Endoplasmic Reticulum Stress
by: Yue Wu, et al.
Published: (2021-07-01)

Hyperphosphorylation of Tau Protein in Hippocampus of Central Insulin-Resistant Rats is Associated with Cognitive Impairment
by: Dantao Peng, et al.
Published: (2013-11-01)

Structural Analysis and Conformational Dynamics of Short Helical Hyperphosphorylated Segments of Tau Protein (Sequence 254–290) in Alzheimer’s Disease: A Molecular Dynamics Simulation Study
by: Mozhgan Alipour, et al.
Published: (2022-08-01)

Developments in the Role of Iron Imbalance in the Pathogenesis of Alzheimer's Disease
by: GUO Shuang, CHEN Fengyan, YIN Xiang, WANG Lu, GUO Xuefeng, YU Qiming, ZOU Zhenyou, SHU Wei
Published: (2022-01-01)

Hyperphosphorylated tau mediates neuronal death by inducing necroptosis and inflammation in Alzheimer’s disease
by: Yue Dong, et al.
Published: (2022-08-01)

Increased MANF Expression in the Inferior Temporal Gyrus in Patients With Alzheimer Disease
by: Xue-Chun Liu, et al.
Published: (2021-04-01)

Metformin a Potential Pharmacological Strategy in Late Onset Alzheimer’s Disease Treatment
by: Saghar Rabiei Poor, et al.
Published: (2021-09-01)

Crosstalk between Cdk5 and GSK3β: Implications for Alzheimer's Disease
by: Olivia Engmann, et al.
Published: (2009-05-01)

Resistance and resilience to Alzheimer’s disease pathology are associated with reduced cortical pTau and absence of limbic-predominant age-related TDP-43 encephalopathy in a community-based cohort
by: Caitlin S. Latimer, et al.
Published: (2019-06-01)

Neuroprotection of Cholinergic Neurons with a Tau Aggregation Inhibitor and Rivastigmine in an Alzheimer’s-like Tauopathy Mouse Model
by: Maciej Zadrozny, et al.
Published: (2024-04-01)

Unravelling the Role of Glycogen Synthase Kinase-3 in Alzheimer’s Disease-Related Epileptic Seizures
by: Runxuan Lin, et al.
Published: (2020-05-01)